Jeffrey T. Barber serves as Independent Director of the Company. Mr. Barber is a Managing Director with Fennebresque & Co., a Charlotte, North Carolina-based investment banking firm, where he focuses on healthcare and technology. Mr. Barber joined Fennebresque & Co. in 2009 after retiring from PricewaterhouseCoopers where he worked for 31 years and served as the Managing Partner of the Raleigh office for 14 years. Mr. Barber previously served on the boards of directors and as chair of the audit committees of Ply Gem Holdings, Inc. from January 2010 through November 2018, SciQuest, Inc. from March 2010 through July 2016 and LipoScience, Inc. from June 2013 through November 2014. He also has served on the Board of Trustees of Blue Cross and Blue Shield of North Carolina since January 2009. Mr. Barber holds a B.S. in Accounting from the University of Kentucky.
As the Independent Director of PRA Health Sciences Inc, the total compensation of Jeffrey Barber at PRA Health Sciences Inc is $220,000. There are 4 executives at PRA Health Sciences Inc getting paid more, with Colin Shannon having the highest compensation of $7,160,220.
Jeffrey Barber is 67, he's been the Independent Director of PRA Health Sciences Inc since 2014. There are no older and 10 younger executives at PRA Health Sciences Inc.
Jeffrey's mailing address filed with the SEC is C/O PRA HEALTH SCIENCES, INC., 4130 PARKLAKE AVENUE, SUITE 400, RALEIGH, NC, 27612.
Over the last 10 years, insiders at PRA Health Sciences Inc have traded over $5,843,308,181 worth of PRA Health Sciences Inc stock. The most active insiders traders include Fund Holdings L.P.Kkr Fund ..., Fund Holdings L.P.Kkr Fund ... a Pra Investors L.P.Kkr Pra I.... On average, PRA Health Sciences Inc executives and independent directors trade stock every 39 days with the average trade being worth of $280,602,577. The most recent stock trade was executed by Christopher L Gaenzle on 17 June 2021, trading 27,497 units of PRAH stock currently worth $2,773,897.
PRA is one of the world's leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA's global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 18,100 employees worldwide. Since 2000, PRA has participated in approximately 4,200 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 100 drugs.
PRA Health Sciences Inc executives and other stock owners filed with the SEC include: